### Section 1.0

### **Instructions**

Complete this form when data collection and the analysis of private identifiable data are complete.

Please answer each question completely – if a question is not applicable, please put N/A in the box.

# **Study Information**

**Study Title:** 

**IRB Number:** 

Initial Approval (if applicable):

**Principal Investigator:** 

Key Study Personnel (if applicable):

Department(s):


Lay Summary:

## Status

Please indicate the study status:

- Never Commenced
- Completed (must have concluded interventions/interventions with human subjects and data analysis are complete)
- Incomplete (no plans to complete the study)

Please state reasons why the study never commenced.



Explain why the study is ending prematurely.



## Section 2.0

## **Study Summary**

Please submit a detailed study summary (3-4 paragraphs should suffice). The study summary must be substantive and complete, and include:

- Goals of the study
- Findings to-date
- Reason(s) why the study is closed

Please address each bullet point; incomplete responses will be sent back to you.

	¶ ▼	≡▼	2 3	•	≔	•	₫	☲	<b>⊗</b>	Ω	•	<u>==</u>	3	
0	Ċ	C												
ject M	Number	rs												
ject l	Number	s												
A. To	<b>Number</b> tal numl	per of s	ubjects dy:	s who	) wer	re								
A. To recru	tal numl ited for imber of	per of si	dy:				in							
A. To recru  B. Nu the s	tal numl ited for imber of	per of sithe stud	ts who	were	e enr	rolled								
A. To recru  B. Nu the si	tal numlited for of tudy:	per of sithe stud	ts who	were	e enr	rolled								

https://byu-dev.imedris.net/System\_Help\_Win.jsp?s=101010101

 $\mathbf{B}$ 

Why did the subject withdraw from the study?

 $\underline{\mathbf{U}}$ 

5

 $\mathbf{x}^{\mathbf{2}}$ 

 $\mathbf{x}_{2}$ 

Font Family

12

1 -	¶ -	<b>≡</b> •	½= 3 ▼	<b>≡</b> •	₫	⅓	O <sub>O</sub>	Ω	<u> </u>	
0	Ċ	C								

### **Adverse Events or Unanticipated Problems**

**Adverse events:** any untoward or unfavorable medical occurence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory findings), symptom, or disease, temporally associated with the subject's participation in the research, whether or not considered related to the subject's participation in the research (modified from the definition of adverse events in the 1996 International Conference on Harmonization E-6 Guidelines for Good Clinical Practice). Adverse events encompass both physical and psychological harms.

**Unanticipated problems:** unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied; related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

Were there any adverse events or unanticipated problems encountered during the study?

○ Yes ○ No

Please explain in detail:



Was the IRB notified of the event or problem?

○ Yes ○ No

Please explain why this was not done:



Publications and Presentations									
Have there been any presenta									
○ Yes ○ No									
Please submit a copy of the at									
Version Title	Category	Expiration Date	Document Outcome	Checked Out	View Document				
No Document(s) have been a									